Monogenic disorders result from defects in a single gene. According to Mendel's laws, these disorders are inherited in either a recessive or dominant fashion. Autosomalrecessive disorders require a disease-causing variant on both alleles, and according to our current understanding, their pathogenicities are not influenced by each other. Here we present an autosomal-recessive disorder, nephrotic syndrome type 2 (MIM 600995), in which the pathogenicity of an NPHS2 allele encoding p.Arg229Gln depends on the trans-associated mutation. We show that, contrary to expectations, this allele leads to a disease phenotype only when it is associated specifically with certain 3′ NPHS2 mutations because of an altered heterodimerization and mislocalization of the encoded p.Arg229Gln podocin. The disease-associated 3′ mutations exert a dominant-negative effect on p.Arg229Gln podocin but behave as recessive alleles when associated with wild-type podocin. Therefore, the transmission rates for couples carrying the disease-associated mutations and p.Arg229Gln may be substantially different from those expected in autosomalrecessive disorders.
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Nephrotic syndrome is the consequence of damage to the glomerular filtration barrier, and it refers to the clinical symptoms of heavy proteinuria, hypoalbuminemia, edema and hyperlipidemia. The steroidresistant form of nephrotic syndrome (SRNS) has a poor prognosis, as it often leads to end-stage renal disease (ESRD) 1, 2 . Mutations in more than 20 genes have been identified in monogenic forms of SRNS, most of which encode podocyte proteins [3] [4] [5] . NPHS2, encoding podocin, is the most frequently mutated of these genes and is responsible for 12-18% of SRNS cases 3, 6, 7 . Podocin accumulates in dimeric or oligomeric forms in lipid raft microdomains at the podocyte slit diaphragm, which is the key component of the glomerular filtration barrier. On the basis of its predicted structure, podocin belongs to the stomatin protein family, with a hairpin-like intramembrane loop and intracellular N and C termini. The C-terminal portions of both stomatin and podocin are responsible for dimerization 6, [8] [9] [10] [11] [12] .
Individuals with NPHS2 mutations typically develop SRNS before 6 years of age and progress to ESRD during their first decade of life 6 . The phenotype can be less severe in the setting of a trans association of an NPHS2 mutation and the polymorphism c.686G>A (p.Arg229Gln, rs61747728), a genotype we hereafter denote as p.
[Arg229Gln]; [mut] that causes SRNS with a median age at diagnosis of 13 years (range, 0-39 years) and progression to ESRD by 26 years (range, 10-50 years) 7, [13] [14] [15] [16] [17] [18] . Nevertheless, the p.Arg229Gln variant in the homozygous state does not cause SRNS 19, 20 .
On the basis of the 15× higher allele frequency of p.Arg229Gln (357/13,006, 2.7%) than the cumulative allele frequency of the known disease-causing variants [13] [14] [15] [16] [17] [18] ( [13] [14] [15] [16] [17] [18] . This substantial (100×) difference between the expected and observed ratios suggested to us that p.[Arg229Gln]; [mut] is not disease causing in the majority of cases.
To test this hypothesis, we screened for p.Arg229Gln in the unaffected parents of affected children with NPHS2 mutations, i.e., unaffected individuals who are obligate mutation carriers. Indeed, out of 129 parents, we found a total of 6 (4.7%), aged 42-62 years, to be compound heterozygous for alleles encoding p.Arg229Gln and one of the following alterations in trans: p.Arg138Gln, p.Arg138* (n = 2), p.Arg168His, c.534+1G>T or p.Arg238Ser. These findings clearly demonstrate the incomplete penetrance of SRNS in p.
[Arg229Gln]; [mut] Mutation-dependent recessive inheritance of NPHS2-associated steroid-resistant nephrotic syndrome l e t t e r s individuals. Nevertheless, the high allele frequency of p.Arg229Gln in late onset SRNS (5.7-7.5%) [16] [17] [18] (Supplementary Fig. 1) .
Out of the 56 mutations located in exons 1-6, only 4 were associated with p.Arg229Gln in cases with SRNS, and these accounted for only 8 of 71 (11%) total p.Arg229Gln-associated alleles (Tables 1 and 2 13, 18 and identified in the French cohort here) Table 2 ) is in agreement with the 100× difference between the expected and observed prevalence of cases with p.
[Arg229Gln]; [mut] . Nevertheless, it cannot be excluded that other rare mutations of exons 7 and 8 are also pathogenic when associated with p.Arg229Gln ( Table 2) .
As all the associated mutations were C-terminal substitutions, we hypothesized that they exert a deleterious effect on p.Arg229Gln podocin. We therefore studied the membrane targeting of p.Arg229Gln npg l e t t e r s podocin in human podocyte cell lines transiently coexpressing different podocin constructs. In perfect accordance with the clinical data, p.Arg229Gln podocin was localized properly to the plasma membrane when coexpressed with wild-type podocin, p.Arg238Ser podocin or p.Val290Met podocin but was retained in the cytoplasm when coexpressed with p.Ala284Val, p.Ala288Thr, p.Arg291Trp, p.Ala297Val or p.Glu310Lys podocin (Supplementary Fig. 2 ). These latter podocin mutants showed a reticular and dispersed vesicular localization pattern similar to that of p.Arg291Trp podocin that is known to be trapped in the endoplasmic reticulum (ER) and vesicles 11, 44 and did not markedly modify the localization of coexpressed wild-type shown superimposed on the wild-type podocin homodimer (green). Accordingly, the root mean square deviations of the backbone atoms compared to those in wild-type podocin were 2.7 Å, 2.9 Å and 3.3 Å for the non-pathogenic dimers shown in a, respectively, and 4.9 Å, 6.9 Å and 9.5 Å for the pathogenic dimers shown in b, respectively. Mobility of the backbone atoms (reflecting the well-defined nature of the structure) remained similar: the mobility was slightly decreased (~30%) in both the dimers of p. Fig. 2) . Furthermore, p.Arg138Gln podocin, which is known to be retained in the ER 10, 11, 44, 45 , did not alter the localization of p.Arg229Gln podocin, which is in accordance with the non-pathogenic nature of their association ( Supplementary  Fig. 2 ). We found similar results in podocytes stably coexpressing wild-type podocin or p.Arg229Gln podocin with podocin mutants (Fig. 1) . Notably, we also confirmed the non-membrane targeting of endogenous podocin in podocytes isolated from urine of a case with p.
[Arg229Gln];[Ala284Val], a result that is contrary to its membranous localization in control patients with p.
[Arg229Gln];[=] ( Fig. 2 and Supplementary Fig. 3) . Thus, all the clinical observations, in vitro studies and ex vivo studies strongly support a deleterious effect of certain podocin mutants on p.Arg229Gln podocin, mimicking a dominant-negative effect. To understand this interaction at an atomic resolution, we examined the calculated structure of their dimers. On the basis of structural modeling, the homodimer of the C-terminal fragment (residues 161-383) of wild-type podocin consists of two head domains (residues 161-270) connected by their intertwined helical tails (residues 271-332), forming a coiled-coil-type association (Fig. 3a) . Arg229 is stabilized in the core of the globular head domain by at least two hydrogen bonds involving Glu233, Glu237 or Asp244 (Fig. 3b) . In p.Arg229Gln podocin, Glu233 and Glu237 are released from these contacts, flip toward the helical tail domain and form electrostatic interactions with Arg286 and Lys289, rigidifying the structure by forming an additional head-tail interaction (Fig. 3b,c) . Nevertheless, both the p.Arg229Gln podocin homodimer and the heterodimer of p.Val290Met podocin with p.Arg229Gln podocin formed a topologically similar molecular arrangement to that of the wild-type homodimer (Fig. 4a) . Moreover, the structure of the heterodimer of p.Ala284Val podocin with wild-type podocin was highly reminiscent of that of the wild-type podocin homodimer as well (Fig. 4a) . In contrast, heterodimers of p.Ala284Val podocin with p.Arg229Gln podocin and of p.Ala297Val podocin with p.Arg229Gln podocin, as well as the p.Ala284Val podocin homodimer, showed characteristically different structures (Fig. 4b) , which is in keeping with their pathogenicities. The derived structures support the conclusion that the combination of the p.Arg229Gln variant with the associated mutations leads to an altered mode of dimerization, which we propose contributes to the retention of p.Arg229Gln podocin within cytoplasmic compartments.
The role of the associated mutations in the pathogenicity of p.Arg229Gln can explain several clinical observations: (i) the difference between the observed and expected prevalence of cases with p. [16] [17] [18] , as p.Arg229Gln podocin homodimers are still expected to function properly.
In conclusion, the NPHS2 allele encoding p.Arg229Gln is only pathogenic when associated with specific mutations. Thus, we describe an autosomal-recessive disorder in which the pathogenicity of one allele depends on that of the other. This phenomenon has direct clinical implications. Unlike current counseling practices, a couple carrying an NPHS2 mutation located in exons 1-6 in one member and p.Arg229Gln in the other are not at risk of having an affected child. Conversely, genetic counseling of couples with p.Arg229Gln and associated mutations will be challenging, as the potential transmission rate of 50% for two unaffected parents, or the potential transmission rates of 25%, 75% or 100% for an affected and an unaffected parent, are not expected in autosomal-recessive disorders ( Supplementary  Fig. 4 ). Other autosomal-recessive disorders may also be inherited in such a mutation-dependent recessive fashion, especially if the encoded protein forms oligomers. In this study, we provide an example of how common variants can be implicated in rare monogenic diseases, thus opening a new aspect in the assessment of the pathogenicity of sequence variants.
URLs. Exome Variant Server, http://evs.gs.washington.edu/EVS/.
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oNLINe MeTHods
Screening of unaffected obligate mutation carriers for p.Arg229Gln. A cohort of 129 parents of 67 children carrying NPHS2 mutations on both alleles but not p.Arg229Gln from the French (n = 117) and Hungarian cohorts (n = 12) was screened for p.Arg229Gln by ClaI digestion. In the case of a positive finding, we used Sanger sequencing to validate the carrier status of the parents for both the transmitted mutation and p.Arg229Gln and to verify their trans position by excluding the carriage of p.Arg229Gln in the affected children. In addition, four grandparents and two uncles of three children with SRNS and p.Val290Met were screened for p.Arg229Gln 41 Analysis of the allele frequency of NPHS2 mutations. Affected individuals (cases) carrying NPHS2 mutations either on both alleles or in association with p.Arg229Gln were compiled from the literature by searching PubMed or were recruited from the French SRNS cohort [13] [14] [15] [16] [17] [18] . A large effort was made to eliminate the possibility of including the same case twice. Thus, cases from the same center with the same age at onset and carrying the same mutations, even if a repeated publication was not indicated, were included only once. Missense variants reported in cases with SRNS were considered to be mutations if they were predicted to be damaging by prediction software (PolyPhen-2, SIFT or MutationTaster). The allele frequency of each mutation was counted in two case groups: (i) cases carrying NPHS2 mutations on both alleles; and (ii) cases carrying an NPHS2 mutation in association with p.Arg229Gln. Homozygous mutations were counted as two alleles.
Generation of podocin-coding plasmids. Human wild-type NPHS2 cDNA was amplified from the construct described by Roselli et al. 11 and subcloned into BamHI and XhoI sites of LentiORF pLEX-MCS (Open Biosystems) or in frame with GFP cDNA into the XhoI and EcoRI sites of pEGFP-N1 (Clontech) and the EcoRV site of pLenti-GIII-CMV (abm) to produce C-terminal GFP fusion proteins. The missense mutations resulting in p.Arg138Gln, p.Arg229Gln, p.Arg238Ser, p.Ala284Val, p.Ala288Thr, p.Val290Met, p.Ala297Val, p.Arg291Trp and p.Glu310Lys were created using the QuikChange Site-Directed Mutagenesis kit according to the manufacturer's instructions (Agilent). Two copies of the HA epitope tag were inserted by mutagenesis in the pLEX-MCS-podocin construct to express N-terminal HA-tagged proteins. Constructs were verified by Sanger sequencing. Midstream freshly voided urine was collected in sterile containers and centrifuged at 2,000 r.p.m. for 10 min. Pelleted cellular material was washed with RPMI medium twice and suspended in RPMI supplemented as described above. Cells were seeded on type I collagen-coated Lab-Tek chamber slides (Thermo Scientific) and grown at 37 °C in 7% CO 2 with medium change every other day.
Generation of podocyte cell lines transiently or stably expressing podocin variants. For transient transfection, podocytes were cultured on type I collagen-coated coverslips and co-transfected with plasmids encoding HAtagged wild-type or HA-tagged p.Arg229Gln podocin and podocin-GFP mutants using FuGENE HD according to the manufacturer's instructions (Promega). To establish the double stable cell lines, podocytes were transduced with lentiviral vectors expressing either the 2HA-tagged wild-type or 2HA-tagged p.Arg229Gln forms of podocin and cultured under puromycin selection (2 µg µl −1 ) for 1 week. Puromycin-resistant cells were then transduced with lentiviral particles encoding either GFP-tagged wild-type or GFP-tagged mutant podocin.
Analysis of the subcellular localization of podocin. Transduced and transfected podocytes were incubated with Alexa Fluor 555-conjugated WGA (W32464, Life Technologies, 1:500) for 20 min at 4 °C to stain the plasma membrane and then fixed with ice-cold ethanol for 5 min. Fixed cells were blocked with PBS and BSA 1% for 15 min and incubated with mouse anti-HA primary antibodies (HA.11 clone 16B12, Covance, 1:500) followed by Alexa Fluor 647-conjugated secondary antibodies (A31571, Life Technologies, 1:200). For urine-derived cells grown in Lab-Tek chamber slides, cells were fixed in cold methanol for 5 min, and the plasma membrane was stained as described above. Then, fixed cells were blocked with PBS and BSA 1% and incubated with rabbit anti-podocin (AP-P35, 1:50) 11 and mouse antisynaptopodin (G1D4, Progen, 1:50) antibodies overnight at 4 °C. Signals were visualized by incubating with the appropriate Alexa Fluor-conjugated antibodies (A31571 and A21206, Life Technologies, 1:200 for both).
Confocal optical slices were captured using a 40× oil objective lens (Leica Microsystems), an optical slice thickness of 800 nm, a Z-step size of 250 nm and an x-y pixel size of 86 nm (Leica SP8 confocal microscope, Necker Imaging Facility). The perimembranous region was defined by delimitating WGAlabeled membrane extensions using ImageJ 1.47i software. The membrane targeting of podocin proteins was characterized by the ratio of the WGAlabeled perimembranous area that colocalized with podocin.
Molecular modeling of podocin dimerization.
A homology model of the podocin monomer was built based on the crystal structure of Pyrococcus horikoshii stomatin 47 (Protein Data Bank (PDB) acquisition code 3BK6 using Prime v3.1 of the Schrödinger Suite (Schrödinger LLC)) ( Supplementary  Fig. 5 ). In the crystal structure of stomatin, a coiled-coil-type association between the helical tail regions of the monomers can be seen. For describing the anti-parallel coiled coil of the podocin dimer, the best sequence fit of such an arrangement from the CC+ database 48 was selected (PDB code 1VP7) where sequence homology was the highest with the corresponding helical region of the podocin monomer. The derived dimer structures were subjected to molecular dynamics simulations as implemented in GROMACS [49] [50] [51] . Systems were solvated by approximately 40,000 TIP3P water molecules, the total charge of the system was neutralized, and the physiological salt concentration was set using Na + and Cl − ions. Energy minimization of the starting structures was followed by sequential relaxation of constraints on the protein atoms in three steps and an additional NVT step (all of 200 ps) to stabilize pressure. Trajectories of 100-ns NPT simulations at 300 K and 1 bar were recorded for further analyses. The average structures of the last 30 ns were compared and were used for analyzing the mobility of the systems (B-factor analysis). The extent of similarity between two average structures was described by fitting their backbones and calculating the root mean square deviation of their corresponding backbone atoms at this best fit. 
Statistical analyses.

